A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Public ClinicalTrials.gov record NCT03052608. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population
Study identification
- NCT ID
- NCT03052608
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 296 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2017 (Actual)
- Primary completion
- Mar 20, 2020 (Actual)
- Completion
- Dec 31, 2028 (Estimated)
- Last update posted
- Nov 25, 2025
2017 – 2028
United States locations
- U.S. sites
- 34
- U.S. states
- 5
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists | Altamonte Springs | Florida | 32701 | — |
| Florida Cancer Specialists | Brandon | Florida | 33511 | — |
| Florida Cancer Specialists | Clearwater | Florida | 33761 | — |
| Florida Cancer Specialists | Gainesville | Florida | 32605 | — |
| Florida Cancer Specialists | Largo | Florida | 33770 | — |
| Florida Cancer Specialists | Lecanto | Florida | 34461 | — |
| Florida Cancer Specialists | Orange City | Florida | 32763 | — |
| Florida Cancer Specialists | Orlando | Florida | 32806 | — |
| Florida Cancer Specialists | Spring Hill | Florida | 34608 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | Tampa | Florida | 33607 | — |
| Florida Cancer Specialists | Tavares | Florida | 32778 | — |
| Florida Cancer Specialists | The Villages | Florida | 32159 | — |
| Florida Cancer Specialists | Winter Park | Florida | 32792 | — |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Ophthalmic Consultants of Boston Inc | Boston | Massachusetts | 02114 | — |
| The William P. Beetham Eye Institute, Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| University of Rochester Cancer Center Pharmacy | Rochester | New York | 14642 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Tennessee Oncology, PLLC | Dickson | Tennessee | 37055 | — |
| Tennessee Oncology, PLLC | Franklin | Tennessee | 37067 | — |
| Tennessee Oncology, PLLC | Gallatin | Tennessee | 37066 | — |
| Tennessee Oncology, PLLC | Hermitage | Tennessee | 37076 | — |
| Tennessee Oncology, PLLC | Lebanon | Tennessee | 37090 | — |
| Tennessee Oncology, PLLC | Murfreesboro | Tennessee | 37129 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute. | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37205 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37207 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37211 | — |
| Tennessee Oncology, PLLC | Shelbyville | Tennessee | 37160 | — |
| Tennessee Oncology, PLLC | Smyrna | Tennessee | 37167 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 132 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03052608, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03052608 live on ClinicalTrials.gov.